<DOC>
	<DOCNO>NCT03101267</DOCNO>
	<brief_summary>The objective study evaluate efficacy , safety , dose-response ASP4070 vaccinate patient cedar pollinosis .</brief_summary>
	<brief_title>A Dose-finding Study ASP4070</brief_title>
	<detailed_description>Subjects vaccinate ASP4070 placebo 2 week interval . Clinical symptom evaluate cedar pollen exposure chamber 4 , 8 12 week last vaccination identify timing onset therapeutic effect .</detailed_description>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject exhibit symptom cedar pollinosis , consist nasal symptom ( sneeze , nasal discharge nasal obstruction ) eye symptom ( itchy eye watery eye ) pollen dispersal season 2016 2017 Subject positive Japanese red cedar ( JRC ) pollenspecific serum IgE antibody test At screening , subject whose score worsen compare baseline 120 180 minute cedar pollen exposure chamber Subject positive test result serum IgE antibody specific antigen JRC pollen screen Subject receive specific immunotherapy ( include desensitization therapy ) cedar pollinosis past Subject receive specific nonspecific immunotherapy within 5 year prior screen Subject receive laser therapy surgery treatment nasal symptom within 3 year prior screen . Subject history allergic reaction anaphylactic shock exanthema generalize cause food and/or medical product past Subject positive test result hepatitis B surface ( HBs ) antigen , antihepatitis C virus ( HCV ) antibody , human immunodeficiency virus ( HIV ) antigen/antibody Subject nasal disease may interfere evaluation Subject autoimmune disease serious primary disease Subject diagnose immunodeficiency past Subject complication seasonal allergic rhinitis ( due allergens Japanese cedar cypress ) , perennial allergic rhinitis , rhinitis medicamentosa , nonallergic rhinitis require medical treatment Subject complication cardiovascular disease Subject complication hepatic disease Subject complication renal disease Subject complication respiratory disease Subject complication malignant tumor diagnose receive treatment malignant tumor within 5 year prior first vaccination study drug Subject diagnose schizophrenia , mental condition Subject complication may impact result local systemic reaction Subject receive vaccination Cry j 2LAMP vaccine Subject participate clinical study ASP4070 receive vaccination study drug .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Cedar pollinosis</keyword>
	<keyword>ASP4070</keyword>
	<keyword>DNA plasmid vaccine</keyword>
</DOC>